Q1 2025 Earnings Call Transcript January 6, 2025 Operator: Hello and welcome everyone to the fiscal 2025 First Quarter ...
L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...
A final clinical study protocol for DefenCath in Total Parenteral Nutrition (TPN) was submitted to FDA in Q4, and study enrollment is expected to begin in H1 2025. The Company also expects patient ...
The OnePlus 13 Mini could be on the way as OnePlus' flagship-level compact smartphone. It could launch in Q1 2025.
Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM), its Ecuadorian subsidiary Curimining S.A. ("Curimining"), and Salazar Resources Limited ("Salazar", together ...